Published On: Sat, Apr 8th, 2017

Broker Changes For Jazz Pharmaceuticals Plc (NASDAQ:JAZZ)


Recently stock market analysts have updated their consensus ratings on shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ).

Most recent broker ratings

04/06/2017 – Jazz Pharmaceuticals plc had its “outperform” rating reiterated by analysts at Leerink Swann. They now have a USD 170 price target on the stock.

04/06/2017 – Jazz Pharmaceuticals plc was upgraded to “buy” by analysts at Janney Montgomery Scott. They now have a USD 175 price target on the stock.

04/06/2017 – Jazz Pharmaceuticals plc had its “overweight” rating reiterated by analysts at Cantor Fitzgerald. They now have a USD 197 price target on the stock.

04/06/2017 – Jazz Pharmaceuticals plc had its “outperform” rating reiterated by analysts at Cowen. They now have a USD 190 price target on the stock.

04/06/2017 – Jazz Pharmaceuticals plc was downgraded to “neutral” by analysts at Mizuho. They now have a USD 150 price target on the stock.

03/20/2017 – Jazz Pharmaceuticals plc had its “outperform” rating reiterated by analysts at BMO Capital Markets. They now have a USD 192 price target on the stock.

03/01/2017 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at Stifel Nicolaus. They now have a USD 190 price target on the stock.

02/22/2017 – Evercore ISI began new coverage on Jazz Pharmaceuticals plc giving the company a “buy” rating. They now have a USD 160 price target on the stock.

02/14/2017 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at Guggenheim. They now have a USD 200 price target on the stock.

01/18/2017 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at UBS. They now have a USD 168 price target on the stock.

01/18/2017 – Jazz Pharmaceuticals plc had its “overweight” rating reiterated by analysts at Barclays. They now have a USD 200 price target on the stock.

01/18/2017 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at Goldman Sachs. They now have a USD 170 price target on the stock.

01/18/2017 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at SunTrust. They now have a USD 210 price target on the stock.

01/18/2017 – Jazz Pharmaceuticals plc had its “buy” rating reiterated by analysts at Deutsche Bank. They now have a USD 148 price target on the stock.

08/10/2016 – Jazz Pharmaceuticals plc had its “overweight” rating reiterated by analysts at Piper Jaffray. They now have a USD 178 price target on the stock.

Jazz Pharmaceuticals plc has a 50 day moving average of 139.56 and a 200 day moving average of 121.98. The stock’s market capitalization is 9.19B, it has a 52-week low of 95.80 and a 52-week high of 160.00.

The share price of the company (NASDAQ:JAZZ) was down -0.06% during the last trading session, with a high of 155.60 and the volume of Jazz Pharmaceuticals plc shares traded was 643913.